The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets

Clinical and Translational Oncology

Volumn 10, Issue 2, 2008, Pages 78-84

  García, M José ^a   Benétez, Javier ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

BRCA1; BRCA2; Breast cancer susceptibility genes; Fanconi anaemia; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; ATM PROTEIN INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYTOTOXIC AGENT; DOUBLE STRANDED DNA; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP B PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP E PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FANCONI ANEMIA GROUP I PROTEIN; FANCONI ANEMIA GROUP J PROTEIN; FANCONI ANEMIA GROUP L PROTEIN; FANCONI ANEMIA GROUP M PROTEIN; FANCONI ANEMIA GROUP N PROTEIN; FANCONI ANEMIA PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; COMBINATION CHEMOTHERAPY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; FAMILIAL CANCER; FANCONI ANEMIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RECOMBINATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; MONOTHERAPY; REVIEW; BREAST TUMOR; FEMALE; GENETICS; PHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FANCONI ANEMIA; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 43749106705     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0160-6     Document Type: Review

References (67)

1. Lopez-Abente G, Pollan M, Aragones N et al (2004) [State of cancer in Spain: Incidence]. An Sist Sanit Navar 27:165-173
2. Houlston RS, Peto J (2004) The search for low-penetrance cancer susceptibility alleles. Oncogene 23:6471-6476
3. Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093
4. Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39:865-869
5. Milne RL, Ribas G, Gonzalez-Neira A et al (2006) ERCC4 associated with breast cancer risk: A two-stage case-control study using high-throughput genotyping. Cancer Res 66:9420-9427
6. Thompson D, Antoniou AC, Jenkins M et al (2005) Two ATM variants and breast cancer risk. Hum Mutat 25:594-595
7. Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59
8. Johnson N, Fletcher O, Palles C et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051-1057
9. Antoniou AC, Pharoah PD, McMullan G et al (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21:1-18
10. Diez O, Osorio A, Duran M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301-312
11. Ford D, Easton DF (1995) The genetics of breast and ovarian cancer. Br J Cancer 72:805-812
12. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333
13. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130
14. García MJ, Fernández V, Osorio A, et al. Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families (submitted)
15. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171-182
16. Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866-871
17. Kim H, Chen J, Yu X (2007) Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316:1202-1205
18. Sobhian B, Shao G, Lilli DR et al (2007) RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316:1198-1202
19. Wang B, Matsuoka S, Ballif BA et al (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316:1194-1198
20. Lu H, Guo X, Meng X et al (2005) The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol 25:1949-1957
21. Joenje H, Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2:446-457
22. Hirano S, Yamamoto K, Ishiai M et al (2005) Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM. EMBO J 24:418-427
23. Akkari YM, Bateman RL, Reifsteck CA et al (2000) DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol Cell Biol 20:8283-8289
24. Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8:735-748
25. Callen E, Casado JA, Tischkowitz MD et al (2005) A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood 105:1946-1949
26. Verlander PC, Kaporis A, Liu Q et al (1995) Carrier frequency of the IVS4 + 4 Azzzz→T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood 86:4034-4038
27. Strathdee CA, Gavish H, Shannon WR, Buchwald M (1992) Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 358:434
28. Medhurst AL, Huber PA, Waisfisz Q et al (2001) Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum Mol Genet 10:423-429
29. Timmers C, Taniguchi T, Hejna J et al (2001) Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 7:241-248
30. Sims AE, Spiteri E, Sims RJ 3rd et al (2007) FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 14:564-567
31. Dorsman JC, Levitus M, Rockx D et al (2007) Identification of the Fanconi anemia complementation group I gene, FANCI. Cell Oncol 29:211-218
32. Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609
33. Alter BP, Rosenberg PS, Brody LC (2007) Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 44:1-9
34. Seal S, Barfoot R, Jayatilake H et al (2003) Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Res 63:8596-8599
35. Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239-1241
36. Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719-729
37. Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159-161
38. Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162-164
39. Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167
40. Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2/ FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 104: 6788-6793
41. Milne RL, Osorio A, Ramón y Cajal T, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counselling units in Spain. Clinical Cancer Research (in press)
42. Erkko H, Xia B, Nikkila J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316-319
43. Kim H, Huang J, Chen J (2007) CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 14:710-715
44. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63: 2585-2588
45. van der Heijden MS, Brody JR, Gallmeier E et al (2004) Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165: 651-657
46. Couch FJ, Johnson MR, Rabe K et al (2005) Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383-386
47. Taniguchi T, Tischkowitz M, Ameziane N et al (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574
48. Narayan G, Arias-Pulido H, Nandula SV et al (2004) Promoter hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994-2997
49. Marsit CJ, Liu M, Nelson HH et al (2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: Implications for treatment and survival. Oncogene 23:1000-1004
50. Jacinto FV, Esteller M (2007) Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22:247-253
51. Rio PG, Pernin D, Bay JO et al (1998) Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int J Oncol 13:849-853
52. Katsama A, Sourvinos G, Zachos G, Spandidos DA (2000) Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett 150:165-170
53. Gallmeier E, Kern SE (2007) Targeting Fanconi anemia/BRCA2 pathway defects in cancer: The significance of preclinical pharmacogenomic models. Clin Cancer Res 13:4-10
54. Kennedy RD, Chen CC, Stuckert P et al (2007) Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117:1440-1449
55. Gallmeier E, Hucl T, Brody JR et al (2007) Highthroughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res 67:2169-2177
56. van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508-7515
57. Nguewa PA, Fuertes MA, Cepeda V et al (2006) Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2:47-53
58. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917
59. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921
60. Schreiber V, Ame JC, Dolle P et al (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277:23028-23036
61. Boulton S, Kyle S, Durkacz BW (1999) Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20:199-203
62. Ratnam K, Low JA (2007) Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13:1383-1388
63. Rubinstein WS (2007) Hereditary breast cancer: Pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer. 2007 Jul 12; (Epub ahead of print)
64. Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL, Benitez J (2007) Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene. 2007 Dec 10; (Epub ahead of print)
65. Honrado E, Osorio A, Milne RL et al (2007) Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 20:1298-1306
66. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874
67. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423